Recommendations for diagnosis and treatment of JIA associated uveitis: Czech-Slovak adaptation of European recommendation SHARE
Authors:
H. Malcová 1; T. Dallos 2; K. Bouchalova 3; I. Brejchová 4; M. Brichová 5; B. Bušányová 6; J. Fabianová 7; J. Fráňová 8; A. Furdová 9; K. Jarošová 10; K. Kobrová 11; B. Kostolná 6; E. Košková 12; M. Lokaj 13; M. Macků 8; J. Melocíková 14; M. Michaličková 5; L. Minxová 15; D. Moravčíková 14; D. Němcová 16; T. Pískovský 17; E. Říhová 5; M. Schüller 7; E. Skalická 18; P. Svozílková 5; D. Tomčíková 6; V. Vargová 19; E. Vrtíková 12; P. Doležalová 16; prof. MUDr. Jarmila Heissigerová, Ph.D., MBA 5
Authors place of work:
Oddělení revmatologie dětí a dospělých, Fakultní nemocnice Motol, Praha, ČR
1; Detská klinika LF UK v Bratislave a NÚDCH, Bratislava, SR
2; Dětská klinika, LF UP a FN Olomouc, ČR
3; Nemocnice České Budějovice, ČR
4; Oční klinika VFN a 1. LF UK, Praha, ČR
5; Klinika detskej oftalmológie LF UK a NÚDCH, Bratislava, SR
6; NUTPCHaHCH Vyšné Hágy I, Vysoké Tatry, SR
7; Pediatrická klinika LF MU a FN Brno, ČR
8; Očná klinika LFUK v Bratislave a UNB, Bratislava, SR
9; Revmatologický ústav, Praha, ČR
10; Dětská klinika Masarykovy nemocnice, Ústí nad Labem, ČR
11; Národný ústav reumatických chorôb, Piešťany, SR
12; Dětská oční klinika LF MU a FN Brno, ČR
13; II. detská klinika SZU DFNsP, Banská Bystrica, SR
14; Dětská klinika LF UK a FN Hradec Králové, ČR
15; Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze, ČR
16; Klinika dětského lékařství, Fakultní nemocnice Ostrava, ČR
17; Dětská klinika LF UK a FN Plzeň, ČR
18; Klinika detí a dorastu, LF UPJŠ Košice, SR
19
Published in the journal:
Čes-slov Pediat 2020; 75 (5): 303-319.
Category:
Summary
Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is its most important extra-articular manifestation. Evidence-based recommendations are available only to a limited extent and therefore JIA associated uveitis management is mostly based on physicians’ experience. Consequently, treatment practices differ widely, both nationally and internationally. Therefore, an effort to optimize and publish recommendations for the care of children and young adults with rheumatic diseases was launched in 2012 as part of the international project SHARE (Single Hub and Access Point for Pediatric Rheumatology in Europe) to facilitate clinical practice for paediatricians and (paediatric) rheumatologists.
Objective: The aim of this work was to translate published international SHARE recommendations for the diagnosis and treatment of JIA associated uveitis and to adapt them for use in the Czech and Slovak Republics.
Methods: International recommendations were developed according to the standard methodology of the European League against Rheumatism (EULAR) by a group of nine experienced paediatric rheumatologists and three experts in ophthalmology. It was based on a systematic literature review and evaluated in the form of an online survey and subsequently discussed using a nominal group techniques. Recommendations were accepted if >80% agreement was reached (including all three ophthalmologists).
Results: A total of 22 SHARE recommendations were accepted: 3 on diagnosis, 5 on disease activity assessment, 12 on treatment and 2 on future recommendations. Translation of the original text was updated and modified with data specific to the czech and slovak health care systems and supplemented with a proposal for a protocol of ophthalmological dispensarization of paediatric JIA patients and a treatment algorithm for JIA associated uveitis.
Conclusion: The aim of the SHARE initiative is to improve and standardize care for paediatric patients with rheumatic diseases across Europe. Therefore, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated based on the evidence and agreement of leading European experts in this field.
Keywords:
recommendation – juvenile idiopathic arthritis (JIA) – Uveitis
Zdroje
1. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017; 76: 329–340.
2. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015; 74: 8–13.
3. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J 2010; 182: E839–842.
4. Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012; 32: 1121–133.
5. Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int 2015; 35: 777–785.
6. Zierhut M, Heiligenhaus A, deBoer J, et al. Controversies in juvenile idio-pathic arthritis-associated uveitis. Ocul Immunol Inflamm 2013; 21: 167–179.
7. Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatric Rheumatology 2016; 14: 27.
8. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idio-pathic arthritis. Nat Rev Rheumatol 2015; 11: 338–348.
9. Zhang W, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301–1311.
10. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312–1324.
11. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004; 63: 1172–1176.
12. Van de Ven AH, Delbecq AL. The nominal group as a research instrument for exploratory health studies. Am J Public Health 1972; 62: 337–342.
13. Uchiyama RC, Osborn TG, Moore TL. Antibodies to iris and retina detected in sera from patients with juvenile rheumatoid arthritis with iridocyclitis by indirect immunofluorescence studies on human eye tissue. J Rheumatol 1989; 16: 1074–1078.
14. Giannini EH, Malagon CN, Van Kerckhove C, et al. Longitudinal analysis of HLA associated risks for iridocyclitis in juvenile rheumatoid arthritis. J Rheumatol 1991; 18: 1394–1397.
15. Malagon C, Van Kerckhove C, Giannini EH, et al. The iridocyclitis of early onset pauciarticular juvenile rheumatoid arthritis: outcome in immunogenetically characterized patients. J Rheumatol 1992; 19: 160–163.
16. Murray KJ, Szer W, Grom AA, et al. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J Rheumatol 1997; 24: 560–567.
17. Berk AT, Koçak N, Ünsal E. Uveitis in juvenile arthritis. Ocul Immunol Inflamm 2001; 9: 243–251.
18. Zulian F, Martini G, Falcini F, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol 2002; 29: 2446–2453.
19. Chia A, Lee V, Graham EM, et al. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol 2003; 135: 757–762.
20. Chen CS, Roberton D, Hammerton ME. Juvenile arthritis-associated uveitis: visual outcomes and prognosis. Can J Ophthalmol 2004; 39: 614–620.
21. Nordal EB, Songstad NT, Berntson L, et al. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol 2009; 36: 1737–1743.
22. Kalinina Ayuso V, Ten Cate HA, van der Does P, et al. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2010; 149: 994–999.
23. Saurenmann RK, Levin AV, Feldman BM, et al. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1824–1828.
24. Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 2013; 40: 2088–2096.
25. Cole TS, Frankovich J, Iyer S, et al. Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research. Pediatr Rheumatol Online J 2013; 11: 45.
26. Calandra S, Gallo MC, Consolaro A, et al. Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. J Rheumatol 2014; 41: 1416–1425.
27. Pelegrín L, Casaroli-Marano R, Antón J, et al. Predictive value of selected biomarkers, polymorphisms, and clinical features for oligoarticular juvenile idiopathic arthritisassociated uveitis. Ocul Immunol Inflamm 2014; 22: 208–212.
28. Egeskjold EM, Johansen A, Permin H, et al. The significance of antinuclear antibodies in juvenile rheumatoid arthritis associated with chronic bilateral iridocyclitis. Acta Paediatr Scand 1982; 71: 615–620.
29. Cabral DA, Petty RE, Malleson PN, et al. Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 1994; 21: 2370–2375.
30. Haas JP, Truckenbrodt H, Paul C, et al. Subtypes of HLA-DRB1*03, *08, *11, *12, *13 and *14 in early onset pauciarticular juvenile chronic arthritis (EOPA) with and without iridocyclitis. Clin Exp Rheumatol 1994; 12 (Suppl 10): S7–14.
31. Kotaniemi K, Kotaniemi A, Savolainen A. Uveitis as a marker of active arthritis in 372 patients with juvenile idiopathic seronegative oligoarthritis or polyarthritis. Clin Exp Rheumatol 2002; 20: 109–112.
32. Zeggini E, Packham J, Donn R, et al. Association of HLA-DRB1*13 with susceptibility to uveitis in juvenile idiopathic arthritis in two independent data sets. Rheumatology 2006; 45: 972–974.
33. Bloom JN, Ni M, Moore TL, et al. Serum antiocular antibodies in patients with juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus 1993; 30: 243–248.
34. Campanilho-Marques R, Bogas M, Ramos F, et al. Prognostic value of antinuclear antibodies in juvenile idiopathic arthritis and anterior uveitis. Results from a systematic literature review. Acta Reumatol Port 2014; 39: 116–122.
35. de Boer J, Steijaert A, van den Bor R, et al. Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2015; 23: 67–73.
36. Ducos de Lahitte G, Terrada C, Tran TH, et al. Maculopathy in uveitis of juvenile idiopathic arthritis: an optical coherence tomography study. Br J Ophthalmol 2008; 92: 64–69.
37. Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 2002; 86: 51–56.
38. Glass D, Litvin D, Wallace K, et al. Early-onset pauciarticular juvenile rheumatoid arthritis associated with human leukocyte antigen-DRw5, iritis, and antinuclear antibody. J Clin Invest 1980; 66: 426–429.
39. Grassi A, Corona F, Casellato A, et al. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease. J Rheumatol 2007; 34: 1139–1145.
40. Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015–1019.
41. Ingegnoli F, Del Papa N, Comina DP, et al. Autoantibodies to chromatin: prevalence and clinical significance in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: 499–501.
42. Kanski JJ. Screening for uveitis in juvenile chronic arthritis. Br J Ophthalmol 1989; 73: 225–228.
43. Kodsi SR, Rubin SE, Milojevic D, et al. Time of onset of uveitis in children with juvenile rheumatoid arthritis. J Aapos 2002; 6: 373–376.
44. Kotaniemi K, Sihto-Kauppi K. Occurrence and management of ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis: An observational series of 104 patients. Clin Ophthalmol 2007; 1: 455–459.
45. Marvillet I, Terrada C, Quartier P, et al. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009; 76: 383–388.
46. Mathur G, Biswas J. Systemic associations of anterior uveitis in a tertiary care ophthalmic centre in south India. Int Ophthalmol 2012; 32: 417–421.
47. McGill NW, Gow PJ. Juvenile rheumatoid arthritis in Auckland: a long term follow-up study with particular reference to uveitis. Aust N Z J Med 1987; 17: 305–308.
48. Melin-Aldana H, Giannini EH, Taylor J, et al. Human leukocyte antigen-DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr 1992; 121: 56–60.
49. Merayo-Lloves J, Power WJ, Rodriguez A, et al. Secondary glaucoma in patients with uveitis. Ophthalmologica 1999; 213: 300–304.
50. Miller ML, Fraser PA, Jackson JM, et al. Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA--DR5 haplotypes. Proc Natl Acad Sci U S A 1984; 81: 3539–3542.
51. Murray P. Serum autoantibodies and uveitis. Br J Ophthalmol 1986; 70: 266–268.
52. Neuteboom GH, Hertzberger-ten Cate R, de Jong J, et al. Antibodies to a 15kD nuclear antigen in patients with juvenile chronic arthritis and uveitis. Invest Ophthalmol Vis Sci 1992; 33: 1657–1660.
53. Ohno S, Char DH, Kimura SJ, et al. HLA antigens and antinuclear antibody titres in juvenile chronic iridocyclitis. Br J Ophthalmol 1977; 61: 59–61.
54. Ostensen M, Fredriksen K, Kass E, et al. Identification of antihistone antibodies in subsets of juvenile chronic arthritis. Ann Rheum Dis 1989; 48: 114–117.
55. Paroli MP, Abbouda A, Restivo L, et al. Juvenile idiopathic arthritis--associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm 2015; 23: 74–81.
56. Paroli MP, Speranza S, Marino M, et al. Prognosis of juvenile rheumatoid arthritisassociated uveitis. Eur J Ophthalmol 2003; 13: 616–621.
57. Reininga JK, Los LI, Wulffraat NM, et al. The evaluation of uveitis in juvenile idiopathic arthritis (JIA) patients: are current ophthalmologic screening guidelines adequate? Clin Exp Rheumatol 2008; 26: 367–372.
58. Sabri K, Saurenmann RK, Silverman ED, et al. Course, complications, and outcome of juvenile arthritis-related uveitis. J Aapos 2008; 12: 539–545.
59. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow up study. Arthritis Rheum 2007; 56: 647–657.
60. Schaller JG, Johnson GD, Holborow EJ, et al. The association of antinuclear antibodies with the chronic iridocyclitis of juvenile rheumatoid arthritis (Still’s disease). Arthritis Rheum 1974; 17: 409–416.
61. Sim KT, Venning HE, Barrett S, et al. Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline. Ocul Immunol Inflamm 2006; 14: 353–357.
62. Southwood TR, Ryder CA. Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis? Br J Rheumatol 1992; 31: 633–634.
63. Wakefield D, Herbort CP, Tugal-Tutkun I, et al. Controversies in ocular inflammation and immunology laser flare photometry. Ocul Immunol Inflamm 2010; 18: 334–340.
64. Wittemann B, Neuer G, Michels H, et al. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1378–1383.
65. Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007; 143: 647–655.
66. Zannin ME, Buscain I, Vittadello F, et al. Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol 2012; 90: 91–95.
67. Kalinina Ayuso V, van de Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217–222.
68. Papadopoulou C, Kostik M, Böhm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879–884.
69. Saboo US, Metzinger JL, Radwan A, et al. Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: a preliminary report. J Aapos 2013; 17: 460–464.
70. Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm 2014; 22: 96–101.
71. Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology 1997; 104: 236–244.
72. Arocker-Mettinger E, Asenbauer T, Ulbrich S, et al. Serum interleukin 2-receptor levels in uveitis. Curr Eye Res 1990; 9 (Suppl 1): 25–29.
73. Kalinina Ayuso V, de Boer JH, Byers HL, et al. Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci 2013; 54: 3709–3720.
74. Heiligenhaus A, Foeldvari I, Edelsten C, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res 2012; 64: 1365–1372.
75. Walscheid K, Hennig M, Heinz C, et al. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis. Invest Ophthalmol Vis Sci 2014; 55: 3447–3453.
76. Manzotti F, Orsoni JG, Zavota L, et al. Autoimmune uveitis in children: clinical correlation between antinuclear antibody positivity and ocular recurrences. Rheumatol Int 2002; 21: 127–132.
77. Massa M, De Benedetti F, Pignatti P, et al. Lack of temporal association of iridocyclitis with IgG reactivities to core histones and nucleosome subparticles in pauciarticular juvenile chronic arthritis. Br J Rheumatol 1995; 34: 507–511.
78. Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 2013; 120: 186–192.
79. Yuce BY, Yilmaz SG, Kose S, et al. Outcome of pediatric uveitis at an university clinic. Turk J Ophthalmol 2013; 43: 395–401.
80. Kotaniemi K, Sihto-Kauppi K, Salomaa P, et al. The frequency and outcome of uveitis in patients with newly diagnosed juvenile idiopathic arthritis in two 4-year cohorts from 1990-1993 and 2000-2003. Clin Exp Rheumatol 2014; 32: 143–147.
81. Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117: 1436–1441.
82. Olson NY, Lindsley CB, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child 1988; 142: 1289–1292.
83. Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology 1987; 94: 1242–1248.
84. Sijssens KM, Rothova A, Van De Vijver DA, et al. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007; 144: 574–579.
85. Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology 1993; 100: 809–817.
86. Yu EN, Meniconi ME, Tufail F, et al. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm 2005; 13: 353–360.
87. Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146–1150.
88. Shetty AK, Zganjar BE, Ellis GS, et al. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 1999; 36: 125–128.
89. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362–365.
90. Heiligenhaus A, Mingels A, Heinz C, et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743–748.
91. Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol 2011; 95: 209–213.
92. Huang JL, Hung IJ, Hsieh KH. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol 1997; 15: 71–75.
93. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008; 115: 1416–1421.
94. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 2009; 23: 1192–1198.
95. Molina C, Modesto C, Martín-Begué N, et al. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol 2013; 32: 1673–1675.
96. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patiens with uveitis treated with infliximab. Ophthalmology 2006; 113: 308–314.
97. Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149: 572–575.
98. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91: 319–324.
99. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007; 91: 1341–1344.
100. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548–550.
101. Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011; 5: 1425–1429.
102. García-De-Vicuńa C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm 2013; 2013: 1–6.
103. Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis associated uveitis. Graefes Arch Clin Exp Ophthalmol 2013; 251: 1601–1606.
104. Zholobova E, Galstian L, Nikolaeva MN, et al. Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis. Pediatric Rheumatology 2014; 12 (Suppl 1): O5.
105. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011; 63: 612–618.
106. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 2013; 11: 16.
107. Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idio-pathic arthritis. J Rheumatol 2018; 45: 1167–1172.
108. William M, Faez S, Papaliodis GN, et al. Golimumab for the treatment of refraktory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2012; 2: 231–233.
109. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252–257.
110. Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005; 33: 461–468.
111. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860–864.
112. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritisassociated chronic anterior uveitis. Rheumatology 2008; 47: 339–344.
113. Trachana M, Pratsidou-Gertsi P, Pardalos G, et al. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol 2011; 40: 101–107.
114. Díaz-Llopis M, Salom D, Garcia-de-Vicuńa C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575–1581.
115. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor – α inhibitor. J Rheumatol 2013; 40: 1394–1403.
116. Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014; 22: 90–95.
117. Saeed MU, Raza SH, Goyal S, et al. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol 2014; 29: 1–3.
118. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005; 44: 1008–1011.
119. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18–23.
120. Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149: 833–836.
121. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010; 35: 751–756.
122. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye 2009; 23: 1868–1870.
123. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010; 62: 821–825.
124. Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390–1394.
125. Mesquida M, Molins B, Llorenç V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology 2014; 121: 2380–2386.
126. Angeles-Han ST, Griffin KW, Lehman TJ, et al. The importance of visual function in the quality of life of children with uveitis. J Aapos 2010; 14: 163–168.
127. Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8-18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res 2011; 63: 1254–1261.
128. Ezzahri M, Amine B, Rostom S, et al. The uveitis and its relationship with disease activity and quality of life in Moroccan children with juvenile idiopathic arthritis. Clin Rheumatol 2013; 32: 1387–1391.
129. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011; 377: 2138–2149.
130. Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 2014; 81: 112–117.
131. Yu HH, Chen PC, Wang LC, et al. Juvenile idiopathic arthritis-associated uveitis: a nationwide population-based study in Taiwan. PLoS One 2013; 5: 8.
132. Shen CC, Yeh KW, Ou LS, et al. Clinical features of children with juvenile idiopathic arthritis using the ILAR classification criteria: a community-based cohort study in Taiwan. J Microbiol Immunol Infect 2013; 46: 288–294.
133. Heiligenhaus A, Heinz C, Edelsten C, et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013; 21: 180–191.
134. Sen, ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis, Best Pract Res Clin Rheumatol 2017; 31: 517–534.
135. Ramanan AV, Guly C. Adalimumab for childhood onset uveitis. Ann Rheum Dis 2018; 77: 961–962.
136. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med 2017; 376: 1637–1646.
137. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology 2018; S0161–6420: 32446–6.
138. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendation from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J 2018; 16: 46.
139. Wieringa WG, Ambrust W, Legger GE, et al. Efficacy of high-dose methotrexate in pediatric non-infectious uveitis. Ocul Immunol Inflamm 2019; 27 (8): 1305–1313.
140. LaMattina KC, Koreishi AF. What is new in pediatric uveitis? Curr Opin Ophtalmol 2018; 29: 412–418.
141. Quartier P, Baptiste A, Despert V on behalf of the ADJUVITE Study Group, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis 2018; 77: 1003–1011.
142. Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol 2017; 35:1043–1046.
143. Skrabl-Baumgartner A, Erwa W, Muntean W, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol 2015; 44: 359–362.
144. Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol 2018; 37: 549–553.
145. Skrabl-Baumgartner A, Seidel G, Langer-Wegscheider B, et al. Drug monitoring in long-term treatment with adalimumab for juvenile idio-pathic arthritis-associated uveitis. Arch Dis Child 2019; 104: 246–250.
146. Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol 2017; 69: 668–675.
147. Tappeiner C, Mesquida M, Adán A, et al. Evidence for Tocilizumab as a treatment option in refractory uveitis associated with juvenile idio-pathic arthritis. J Rheumatol 2016; 43: 2183–2188.
148. Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina 2018; 38: 1361–1370.
149. Ramanan A, Dick AD, Jones AP, et al. A phase II trial protocol of tocilizumab in ati-TNF refraktory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol 2018; 2: 1.
150. Ferrara M, Eggenschwiler L, Stephenson A, et al. The Challenge of Pediatric Uveitis: Tertiary Referral Center Experience in the United States. Ocul Immunol Inflamm 2018; 15: 1–8.
151. Pleyer U, Algharably EA, Feist E, et al. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother 2017; 18: 1311–1323.
152. Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 2019; 49 (1): 43–55.
153. Foeldvari I, Klotsche J, Simonini G, et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). Pediatr Rheumatol Online J 2019; 17 (1): 66.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2020 Číslo 5
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Prof. MUDr. Jiří ZEMAN, DrSc. – jubileum
- COVID-19 pandemy from the perspective of regional children´s clinic
- Anemia in children with inflammatory bowel diseases
- Abdominal pain caused by retrocaval ureter